Syndax Pharmaceuticals (SNDX) Invested Capital (2016 - 2025)
Historic Invested Capital for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Q3 2025 value amounting to $115.4 million.
- Syndax Pharmaceuticals' Invested Capital fell 6849.89% to $115.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $115.4 million, marking a year-over-year decrease of 6849.89%. This contributed to the annual value of $300.2 million for FY2024, which is 4582.42% down from last year.
- Per Syndax Pharmaceuticals' latest filing, its Invested Capital stood at $115.4 million for Q3 2025, which was down 6849.89% from $157.4 million recorded in Q2 2025.
- In the past 5 years, Syndax Pharmaceuticals' Invested Capital ranged from a high of $554.2 million in Q4 2023 and a low of $115.4 million during Q3 2025
- In the last 5 years, Syndax Pharmaceuticals' Invested Capital had a median value of $366.4 million in 2024 and averaged $339.7 million.
- Its Invested Capital has fluctuated over the past 5 years, first surged by 21674.62% in 2021, then plummeted by 6849.89% in 2025.
- Over the past 5 years, Syndax Pharmaceuticals' Invested Capital (Quarter) stood at $408.6 million in 2021, then increased by 14.42% to $467.4 million in 2022, then rose by 18.56% to $554.2 million in 2023, then tumbled by 45.82% to $300.2 million in 2024, then crashed by 61.55% to $115.4 million in 2025.
- Its last three reported values are $115.4 million in Q3 2025, $157.4 million for Q2 2025, and $215.1 million during Q1 2025.